Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Tommy G. ThompsonDirector | TherapeuticsMDTXMD | Open-market buy | 25/12/23 | 25/12/29 | 8,400 sh | $1.67 | $14,028 | +56.8% |
Tommy G. ThompsonDirector | TherapeuticsMDTXMD | Open-market buy | 25/04/14 | 25/04/15 | 325 sh | $1.00 | $325 | +2.2% |
TherapeuticsMDTXMD | Open-market buy | 25/04/14 | 25/04/15 | 490 sh | $1.00 | $490 | +0.7% | |
TherapeuticsMDTXMD | Open-market buy | 25/04/09–25/04/10 | 25/04/10 | 2,303 sh2 trades | $0.86avg. | $1,991.94 | +3.3% | |
Cooper C. CollinsDirector | TherapeuticsMDTXMD | Open-market buy | 24/08/22 | 24/08/26 | 4,094 sh | $1.73 | $7,082.62 | +8.5% |
Cooper C. CollinsDirector | TherapeuticsMDTXMD | Open-market buy | 24/08/21 | 24/08/23 | 1,200 sh | $1.70 | $2,040 | +2.6% |
TherapeuticsMDTXMD | Open-market sale | 23/12/06–23/12/07 | 23/12/07 | 19,050 sh2 trades | $2.29avg. | $43,687 | −23.3% | |
TherapeuticsMDTXMD | Open-market saleAmendment | 23/04/26 | 23/05/04 | 692 sh | $3.64 | $2,518.88 | −5.6% | |
TherapeuticsMDTXMD | Open-market sale | 23/04/12 | 23/04/14 | 1,170 sh | $3.65 | $4,270.5 | −8.7% | |
TherapeuticsMDTXMD | Open-market sale | 23/01/26–23/01/27 | 23/01/30 | 1,697 sh2 trades | $5.08avg. | $8,621.25 | −12.5% | |
TherapeuticsMDTXMD | Open-market sale | 23/01/23–23/01/24 | 23/01/25 | 1,309 sh2 trades | $5.34avg. | $6,989.85 | −14.7% | |
Rubric Capital Management10% Owner | TherapeuticsMDTXMD | Open-market sale | 22/12/30 | 23/01/03 | 29,000 sh | $1,333.00 | $38,657,000 | −100.0% |
David Efraim Rosen10% Owner | TherapeuticsMDTXMD | Open-market sale | 22/12/30 | 23/01/03 | 29,000 sh | $1,333.00 | $38,657,000 | −100.0% |